Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Reiss, B. Knorr, J. L. Marchal, M. P. Malice, H. Bisgaard (Rahway, NJ, United States Of America; Copenhagen, Denmark). Post-hoc analysis of the effect of montelukast in treating post-RSV-bronchiolitic respiratory symptoms in children. Eur Respir J 2007; 30: Suppl. 51, 2715

Member's Comments

No comment yet.

Related content which might interest you: Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Inhaled antibiotics improve symptoms of cough and sputum in patients with bronchiectasis: a post-hoc analysis of the AIR-BX studies Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Exploratory trial on cough reflex sensitivity in patients with acute cough during URTI and post recovery. Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Comparative analysis of prevalence and severity of bronchial asthma symptoms at 7–8-year-old and 13–14-year-old children Source: Eur Respir J 2006; 28: Suppl. 50, 250s Year: 2006 Clustering of respiratory symptoms in patients with a positive histamine challenge test Source: Eur Respir J 2004; 24: Suppl. 48, 83s Year: 2004 Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Safety of montelukast in children with post-RSV-bronchiolitic respiratory symptoms Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Effect of COVID19 preventive measures on respiratory infections and symptoms in children Source: Virtual Congress 2021 – Causes and consequences of paediatric respiratory diseases Year: 2021 Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Efficacy of multivariate analysis in differentiating between asthma and COPD in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 275s Year: 2005 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 The effect of inhaled corticosteroids on symptoms in pre-school children with asthma-like symptoms in general practice: the ASTERISK study Source: Eur Respir J 2004; 24: Suppl. 48, 165s Year: 2004 Does fluticasone or montelukast reduce the risk of recurency of wheezing bronchitis comparing to no intervention in children under the age of 3 Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 LRT infections aetiology in hospitalized children and its importance for asthma exacerbation Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004 Reducing the frequency of respiratory tract infections in severe neurological disorders by inhaled antibiotics: a retrospective data analysis Source: ERJ Open Res, 5 (3) 00149-2018; 10.1183/23120541.00149-2018 Year: 2019 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015